The importance
of complete
molecular
profiling

The importance of complete molecular profiling

There are many genomic alterations that can play a role in HNSCC so it is important to test for different biomarkers. After initial testing, a full molecular workup may identify new, relevant biomarkers that may inform the next course of action following disease progression1-4:

noun_gemology_3819001

Diagnostic biomarkers detect cancer and identify the specific disease5

noun_Track_2473284

Predictive biomarkers are used to help select the best treatment and predict patient response5

noun_face identification_2517178

Prognostic biomarkers identify the likely clinical outcome (independent of treatment received)5

noun_Business and Marketing Concepts_1825095

Monitoring biomarkers help to track a patient’s response to therapy5

WHEN to test for biomarkers

Testing icon

In patients with HNSCC, it is important to test for biomarkers, such as HRAS and PIK3CA, upon both locally advanced and metastatic diagnosis to determine the appropriate treatment path, including current investigational clinical trials that are actively enrolling for these populations.1

After initial testing, a full molecular workup may identify new, relevant biomarkers that may inform the next course of action following disease progression.3

In a study of 46 HNSCC patients, 6 of 13 patients with progressive disease during cetuximab-based treatment showed evidence of acquired RAS mutations. Three of the 6 acquired mutations were HRAS mutations.3

HOW to test for HRAS and PIK3CA

Biomarker testing can help you to discover cancer drivers and determine the best course of action for your patients with HNSCC. Early next-generation sequencing (NGS) can be used to uncover HRAS mutations and PIK3CA mutations and amplifications, and immunohistochemistry (IHC) can be used to determine HRAS overexpression.1,4 Commercially available genomic panels include:
Biomarker

HRAS mutations

PIK3CA mutations and amplifications

HRAS overexpression

Assay

FoundationOne Liquid CDx®

Tempus® xT®

Caris Molecular Intelligence CANCERPLEX®

Paradigm PCDx™

Guardant360

Oncomine® Comprehensive Assay

PGDx elio™

No commercial panels. Send to lab for IHC analysis.